SynCore Biotechnology Co

SynCore Biotechnology Co Financing Cash Flow

The Net Financing Cash Flow of SynCore Biotechnology Co (4192.TWO) as of Nov 11, 2026 is 78.68 M TWD. In the previous year, Net Financing Cash Flow was -73.21 M TWD — a change of -207.46% (higher).

Financing Cash Flow

78.68 MTWD

YoY

-207.46%

Last updated:

Net Financing Cash Flow of SynCore Biotechnology Co is 2023 78.68 M TWD. Net Financing Cash Flow of SynCore Biotechnology Co was 2022 -73.21 M TWD. It decreases by -207.46% higher compared to the previous year.

The SynCore Biotechnology Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2016
310.70 M TWD
Jan 1, 2017
-33.46 M TWD
Jan 1, 2018
288.87 M TWD
Jan 1, 2019
335.76 M TWD
Jan 1, 2020
475.13 M TWD
Jan 1, 2021
245.31 M TWD
Jan 1, 2022
-73.21 M TWD
Jan 1, 2023
78.68 M TWD
The SynCore Biotechnology Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
78.68 MTWD-207.46%
-73.21 MTWD-129.84%
245.31 MTWD-48.37%
475.13 MTWD+41.51%
335.76 MTWD+16.23%
288.87 MTWD-963.42%
-33.46 MTWD-110.77%
310.70 MTWD0.00%
310.70 MTWD-47.12%
587.56 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SynCore Biotechnology Co Stock analysis

What does SynCore Biotechnology Co do? SynCore Biotechnology Co Ltd, based in Dongshan, Yilan, Taiwan, operates in the Health Care sector with a focus on Pharmaceuticals. The company develops new drugs and integrates technology, employing 50 full-time staff. Its main product is SB03 Veregen, alongside research and development of anticancer drugs SB01 (injection and oral forms). SynCore primarily distributes its products within Taiwan. SynCore Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SynCore Biotechnology Co stock

Net Financing Cash Flow of SynCore Biotechnology Co is 78.68 M TWD in 2023.

Net Financing Cash Flow of SynCore Biotechnology Co changed from -73.21 M TWD to 78.68 M TWD, representing a -207.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow SynCore Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's SynCore Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — SynCore Biotechnology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — SynCore Biotechnology Co